Eisai Showcases Real-World Lecanemab Data, Pushes for Standardized Alzheimer's Treatment
Event summary
- Eisai will present 14 presentations, including four oral presentations, on lecanemab (LEQEMBI®) at the 2026 American Academy of Neurology (AAN) Annual Meeting.
- The presentations will focus on real-world treatment data, biomarker insights, and long-term clinical outcomes of lecanemab.
- Eisai is hosting a symposium on 'smoldering Alzheimer's disease,' a concept describing the slow progression of the disease decades before clinical symptoms.
- Lecanemab has received approval in 53 countries and regions, including the U.S., China, and Japan, with applications pending in 6 additional countries.
The big picture
Eisai's focus on real-world evidence and standardized treatment frameworks signals a shift towards demonstrating the long-term value of lecanemab beyond clinical trial results. The emphasis on 'smoldering Alzheimer's disease' suggests a broader strategy to address the disease at earlier stages, potentially expanding the patient population and creating new market opportunities. This strategy is being co-commercialized with Biogen, creating a complex governance structure that will influence decision-making and resource allocation.
What we're watching
- Adoption Rate
- The extent to which the presented real-world data influences physician adoption of lecanemab will be a key indicator of its long-term commercial success, particularly given the drug's cost and safety profile.
- Regulatory Landscape
- The acceptance of subcutaneous formulations and expanded indications, as evidenced by the pending sBLA in the U.S., will dictate the drug's accessibility and market penetration.
- Competitive Dynamics
- The emergence of 'smoldering Alzheimer's disease' as a recognized clinical concept could shift the focus towards earlier intervention and potentially accelerate the development of competing therapies.
Related topics